Sotera Health (NASDAQ:SHC) Trading Down 5.2% – Should You Sell?

Sotera Health (NASDAQ:SHC)’s share price dropped 5.2% during trading on Wednesday . The company traded as low as $12.79 and last traded at $12.90. Approximately 851,002 shares were traded during trading, a decline of 34% from the average daily volume of 1,298,385 shares. The stock had previously closed at $13.61.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SHC. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a report on Thursday. Citigroup boosted their price target on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, Barclays increased their price objective on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.50.

Sotera Health Stock Performance

The firm has a market capitalization of $3.57 billion, a price-to-earnings ratio of 49.64 and a beta of 2.08. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The stock’s 50-day moving average is $15.69 and its 200-day moving average is $13.93.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The company had revenue of $285.47 million for the quarter, compared to analyst estimates of $278.64 million. During the same quarter last year, the company posted $0.18 earnings per share. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. On average, analysts predict that Sotera Health will post 0.61 EPS for the current fiscal year.

Insider Transactions at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the completion of the transaction, the director now owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. This trade represents a 16.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 55.12% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sotera Health

A number of hedge funds have recently bought and sold shares of the company. Neo Ivy Capital Management acquired a new stake in Sotera Health in the third quarter worth $720,000. Geode Capital Management LLC boosted its position in shares of Sotera Health by 19.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock worth $46,026,000 after purchasing an additional 447,186 shares in the last quarter. Barclays PLC grew its stake in shares of Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company’s stock valued at $7,909,000 after buying an additional 298,085 shares during the period. Public Employees Retirement System of Ohio increased its position in Sotera Health by 14.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 54,706 shares of the company’s stock valued at $914,000 after buying an additional 6,826 shares in the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in Sotera Health during the 3rd quarter worth approximately $259,000. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.